Skip to main content
OpenTrials
Completed

NCT Number: NCT00840203

Mesalamine 4 gm/60 mL Rectal Enema

The objective of this study is to evaluate the relative bioavailability of the test formulation of mesalamine suspension rectal enema with the already marketed reference formulation Rowasa® in healthy, adult subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Novum Pharmaceutical Research Services

Pittsburgh, Pennsylvania, 15206, United States

About this study

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females, 18 years or older, with a body mass index (BMI) of 30 or less.
  • Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
  • Signed informed consent form, which meets all criteria of current FDA regulations.
  • If female and of child bearing potential prepared to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g. condom, IUD, hormonal contraceptives).

Exclusion criteria

  • If female pregnant, lactating, or likely to become pregnant during the study.
  • History of allergy or sensitivity to mesalamine or other salicylic drugs (e.g. aspirin, sulfasalazine) or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  • Colitis, hemorrhoids, anal fissures, or other disease of the anus, rectum or colon.
  • Significant history or current evidence of chronic infections disease, system disorder or organ disorder.
  • History of psychiatric disorders occuring within the last two years that required hospitalization or medication.
  • Presence of a medical condition requiring regular treatment with prescription drugs (other than contraceptives).
  • Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
  • Receipt of any drug as part of a research study within 30 days prior to dosing.
  • Drug or alcohol addiction requiring treatment in the past 12 months.
  • Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days prior to dosing.
  • Positive test for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
  • Positive test results for drugs of abuse at screening.
  • Positive serum pregnancy test at screening.
  • Unable or unwilling to tolerate multiple venipunctures.

Treatment and study plan

Rowasa® 4 gm/60 mL Rectal Enema

Drug

1 x 4 gm/60 mL, single-dose

Mesalamine 4 gm/60 mL Rectal Enema

Drug

1 x 4 gm/60 mL, single-dose

Primary outcomes

  1. Cmax - Maximum Observed Concentration

    Time frame: Blood samples collected over 48 hour period

    Bioequivalence based on Cmax

  2. AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Time frame: Blood samples collected over 48 hour period

    Bioequivalence based on AUC0-inf

  3. AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

    Time frame: Blood samples collected over 48 hour period

    Bioequivalence based on AUC0-t

Secondary outcomes

  1. Cmax - Maximum Observed Concentration

    Time frame: Blood samples collected over 48 hour period

    Cmax results for N-Acetylmesalamine metabolite

  2. AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Time frame: Blood samples collected over 48 hour period

    AUC0-inf results for N-Acetylmesalamine metabolite

  3. AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

    Time frame: Blood samples collected over 48 hour period

    AUC0-t results for N-Acetylmesalamine metabolite

Sponsors and collaborators

Lead sponsor

Teva Pharmaceuticals USA

Industry

Registry information

Official study title

A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 mL Rectal Enema Formulations

Important dates

Study start
2003
Primary completion
2003
Study completion
2003
First posted
Feb 10, 2009
Registry last updated
Aug 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.